secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-06-26T11:15:32+00:00
Accession:  0001193125-26-283906
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences appoints Mark Eisner, former Vir CMO, to Board of Directors
----------------------------------------------------------------------------

- Mark Eisner appointed as Class I director effective June 25, 2026; joins Nominating and Corporate Governance Committee.
- Eisner most recently EVP & CMO at Vir Biotechnology; previously CMO at Sonoma Biotherapeutics and FibroGen, and 11 years at Genentech/Roche.
- Received option for 47,675 shares vesting over 3 years; eligible for annual cash retainer under non-employee director program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526283906/0001193125-26-283906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526283906/d127137d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-283906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer